Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers

Rebeca Lozano; Elena Castro; Fernando López‐Campos; Heather Thorne; M. Backhaus; Isabel M. Aragón; Ylenia Cendón; Ana Gutiérrez-Pecharromán; Daniela C. Salles; Nuria Romero-Laorden; David Lorente; Pilar Gónzalez‐Peramato; Ana Calatrava; Concepción Alonso; Urbano Anido; Sara Arévalo-Lobera; Judith Balmañà; Isabel Chirivella; María José Juan-Fita; Gemma Llort; Teresa Ramón y Cajal; Elena Almagro; Daniel Alameda; Pedro P. López‐Casas; Bernardo Herrera; Joaquı́n Mateo; Colin C. Pritchard; Emmanuel S. Antonarakis; Tamara L. Lotan; J. Rubio‐Briones; Shahneen Sandhu; David Olmos

doi:10.1016/j.ejca.2023.02.022

Related publications

Letter2013

Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer

Shahneen Sandhu, Aurelius Omlin, Lucy Hylands, Susana Miranda, Louise J. Barber, Ruth Riisnaes, Alison Reid, Gerhardt Attard, L. Chen, Iwanka Kozarewa, Heidi Gevensleben, James Campbell, Kerry Fenwick, Ioannis Assiotis, David Olmos, Timothy A. Yap, Peter C.C. Fong, Nina Tunariu, Dow‐Mu Koh, L. Rhoda Molife, S.B. Kaye, Christopher J. Lord, Alan Ashworth, Johann S. de Bono

Article2023

BRCA1 and BRCA2 carriers with breast, ovarian and prostate cancer demonstrate a different pattern of metastatic disease compared with non‐carriers: results from a rapid autopsy programme

Heather Thorne, Lisa Devereux, Jason Li, Kathryn Alsop, Liz Christie, Courtney T. van Geelen, Nikki Burdett, Kathleen I. Pishas, Noel Woodford, Jodie Leditschke, Mohamed H M A Izzath, Kate Strachan, Greg Young, Rufaro Diana Jaravaza, Mohammed Madadin, Melanie S. Archer, Joanna Glengarry, Linda Iles, Ajith Rathnaweera, Clare Hampson, Khamis Almazrooei,

Article2020

The tumor immune microenvironment of germline BRCA1/2 and sporadic prostate cancer.

Anna Trigos, Anupama Pasam, Patricia Banks, Roslyn Wallace, Simon P. Keam, Heather Thorne, Catherine Mitchell, David Clouston, Declan G. Murphy, Nathan Lawrentschuk, Damien Bolton, Daniel Moon, Elena Castro, David Olmos, Phillip K. Darcy, Ygal Haupt, Scott Williams, David L. Goode, Paul J. Neeson, Shahneen Sandhu

Article2015

BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers

Huong Meeks, Honglin Song, Kyriaki Michailidou, Manjeet K. Bolla, Joe Dennis, Qin Wang, Daniel Barrowdale, Debra Frost, Lesley McGuffog, Ian O. Ellis, Bing Feng, Saundra S. Buys, John L. Hopper, Melissa C. Southey, Andrea Tesoriero, Paul A. James, Fiona Bruinsma, Ian Campbell, Annegien Broeks, Marjanka K. Schmidt, Frans B.L. Hogervorst, Matthias W. Beckman, Peter A. Fasching, Olivia Fletcher, Nichola Johnson,

Article2020

612MO Clinical impact of somatic alterations in prostate cancer patients with and without previously known germline BRCA1/2 mutations: Results from PROREPAIR-A study

R. Lozano Mejorada, E. Castro Marcos, Isabel M. Aragón, Heather Thorne, Fernando López‐Campos, Alejandro Sanz-Carbonell, C. Alonso, Urbano Anido, M.J. Juan Fita, A.M. Gutierrez Pecharromán, M. Backhaus, Judith Balmañà, Isabel Chirivella González, Gemma Llort, Nuria Romero-Laorden, Sara Arévalo Lobera, J. Rubio‐Briones, Colin C. Pritchard, Shahneen Sandhu, David Olmos

Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers

Discussion(0)

Related publications

Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer

<i>BRCA1</i> and <i>BRCA2</i> carriers with breast, ovarian and prostate cancer demonstrate a different pattern of metastatic disease compared with non‐carriers: results from a rapid autopsy programme

The tumor immune microenvironment of germline <i>BRCA1/2</i> and sporadic prostate cancer.

BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers

612MO Clinical impact of somatic alterations in prostate cancer patients with and without previously known germline BRCA1/2 mutations: Results from PROREPAIR-A study